Pharmacotherapeutic management of bronchial infections in adults: non-cystic fibrosis bronchiectasis and chronic obstructive pulmonary disease

References

• Dasaraju PV, Liu C. Infections of the respiratory system. In: editor, Baron S. Medical Microbiology. 4th ed. Galveston: University of Texas Medical Branch at Galveston; 1996. Chapter 93.
   Google Scholar
• Hill AT, Haworth CS, Aliberti S, et al. Pulmonary exacerbation in adults with bronchiectasis: a consensus definition for clinical research. Eur Respir J. 2017;49:1700051.
   PubMed Web of Science ®Google Scholar
• Chalmers JD, Goeminne P, Aliberti S, et al. The bronchiectasis severity index an international derivation and validation study. Am J Respir Crit Care Med. 2014;189:576–585.
   PubMed Web of Science ®Google Scholar
• Global Initiative for Chronic Obstructive Lung Disease (GOLD). Global Strategy for the Diagnosis, Management and Prevention of COPD; 2019. Available from: http://goldcopd.org/gold-2019-global-strategy-diagnosismanagement-prevention-copd/GOLD
   Google Scholar
• Polverino E, Goeminne PC, McDonnell MJ, et al. European Respiratory Society guidelines for the management of adult bronchiectasis. Eur Respir J. 2017;50:1700629.
   PubMed Web of Science ®Google Scholar
• Wu Q, Shen W, Cheng H, et al. Long-term macrolides for non-cystic fibrosis bronchiectasis: a systematic reviewand meta-analysis. Respirology. 2014;19:321–329.
   PubMed Web of Science ®Google Scholar
• Yang JW, Fan LC, Lu HW, et al. Efficacy and safety of long-term inhaled antibiotic for patients with noncysticfibrosis bronchiectasis: a meta-analysis. Clin Respir J. 2016;10:731–739.
   PubMed Web of Science ®Google Scholar
• Doll H, Miravitlles M. Health-related QOL in acute exacerbations of chronic bronchitis and chronic obstructive pulmonary disease: a review of the literature. Pharmacoeconomics. 2005;23(4):345–363.
   PubMed Web of Science ®Google Scholar
• Donaldson GC, Seemungal TA, Bhowmik A, et al. Relationship between exacerbation frequency and lung function decline in chronic obstructive pulmonary disease. Thorax. 2002;57(10):847–852.
   PubMed Web of Science ®Google Scholar
• Mantero M, Rogliani P, Di Pasquale M, et al. Acute exacerbations of COPD: risk factors for failure and relapse. Int J Chron Obstruct Pulmon Dis. 2017 Sep 8;12:2687–2693.
   PubMed Web of Science ®Google Scholar
• Clark TW, Medina M-J, Batham S, et al. Adults hospitalised with acute respiratory illness rarely have detectable bacteria in the absence of COPD or pneumonia; viral infection predominates in a large prospective UK sample. J Infect. 2014;69(5):507–515.
   PubMed Web of Science ®Google Scholar
• Widmer K, Zhu Y, Williams JV, et al. Rates of hospitalizations for respiratory syncytial virus, human metapneumovirus, and influenza virus in older adults. J Infect Dis. 2012;206(1):56–62.
   PubMed Web of Science ®Google Scholar
• McDonnell MJ, Aliberti S, Goeminne PC, et al. Comorbidities and the risk of mortality in patients with bronchiectasis: an international multicentre cohort study. Lancet Respir Med. 2016;4:969–979.
   PubMed Web of Science ®Google Scholar
• Pasteur MC, Bilton D, Hill AT, et al. British Thoracic Society guideline for non-CF bronchiectasis. Thorax. 2010;65(Suppl. 1):i1–i58.
   PubMed Web of Science ®Google Scholar
• Chalmers JD, Smith MP, McHugh BJ, et al. Short- and long-term antibiotic treatment reduces airway and systemic inflammation in non-cystic fibrosis bronchiectasis. Am J Respir Crit Care Med. 2012;186:657–665.
   PubMed Web of Science ®Google Scholar
• Polverino E, Menendez R, Cilloniz C, et al. Microbial aetiology and outcomes of CAP in bronchiectatic patients. Eur Respir J. 2013;42:4646.
   Web of Science ®Google Scholar
• Tunney MM, Einarsson GG, Wei L, et al. Lung microbiota and bacterial abundance in patients with bronchiectasis when clinically stable and during exacerbation. Am J Respir Crit Care Med. 2013;187:1118–1126.
   PubMed Web of Science ®Google Scholar
• Rogers GB, van der Gast CJ, Cuthbertson L, et al. Clinical measures of disease in adult non-CF bronchiectasis correlate with airway microbiota composition. Thorax. 2013;68:731–737.
   PubMed Web of Science ®Google Scholar
• Dickson RP, Martinez FJ, Huffnagle GB. The role of the microbiome in exacerbations of chronic lung diseases. Lancet. 2014;384:691–702.
   PubMed Web of Science ®Google Scholar
• Gao YH, Guan WJ, Xu G, et al. The role of viral infection in pulmonary exacerbations of bronchiectasis in adults: a prospective study. Chest. 2015;147:1635–1643.
   PubMed Web of Science ®Google Scholar
• Murray MP, Turnbull K, Macquarrie S, et al. Assessing response to treatment of exacerbations of bronchiectasis in adults. Eur Respir J. 2009;33:312–318.
   PubMed Web of Science ®Google Scholar
• MÁ M-G, Máiz L, Olveira C, et al. Spanish guidelines on treatment of bronchiectasis in adults. Arch Bronconeumol. 2018;54:88–98.
   PubMed Web of Science ®Google Scholar
• Vendrell M, de Gracia J, Olveira C, et al. Normativa SEPAR: diagnóstico y tratamiento de las bronquiectasias. [Diagnosis and treatment of bronchiectasis. Spanish Society of Pneumology and Thoracic Surgery.]. Arch Bronconeumol. 2008;44:629–640.
   PubMed Web of Science ®Google Scholar
• Gillham MI, Sundaram S, Laughton CR, et al. Variable antibiotic susceptibility in populations of Pseudomonas aeruginosa infecting patients with bronchiectasis. J Antimicrob Chemother. 2009;63:728–732.
   PubMed Web of Science ®Google Scholar
• Foweraker JE, Laughton CR, Brown DF, et al. Comparison of methods to test antibiotic combinations against heterogeneous populations of multiresistant Pseudomonas aeruginosa from patients with acute infective exacerbations in cystic fibrosis. Antimicrob Agents Chemother. 2009;53:4809–4815.
   PubMed Web of Science ®Google Scholar
• Bilton D, Henig N, Morrissey B, et al. Addition of inhaled tobramycin to ciprofloxacin for acute exacerbations of Pseudomonas aeruginosa infection in adult bronchiectasis. Chest. 2006;130:1503–1510.
   PubMed Web of Science ®Google Scholar
• Menéndez R, Méndez R, Polverino E, et al. Risk factors for multidrug-resistant pathogens in bronchiectasis exacerbations. BMC Infect Dis. 2017;17:659.
   PubMed Web of Science ®Google Scholar
• Gao Y, Guan W, Zhu Y, et al. Antibiotic-resistant Pseudomonas aeruginosa infection in patients with bronchiectasis: prevalence, risk factors and prognostic implications. Int J Chron Obstruct Pulmon Dis. 2018;13:237–246.
   PubMed Web of Science ®Google Scholar
• Lee CR, Cho IH, Jeong BC, et al. Strategies to minimize antibiotic resistance. Int J Environ Res Public Health. 2013;10:4274–4305.
   PubMed Web of Science ®Google Scholar
• Pressler T, Bohmova C, Conway S, et al. Chronic Pseudomonas aeruginosa infection definition: euroCareCF Working Group report. J Cyst Fibros. 2011;10:S75–S78.
   PubMed Web of Science ®Google Scholar
• Martinez-Garcia MA, Athanazio RA, Girón R, et al. Predicting high risk of exacerbations in bronchiectasis: the E-FACED score. Int J Chron Obs Pulmon Dis.. 2017;18:275–284.
   Web of Science ®Google Scholar
• Tamaoki J. The effects of macrolides on inflammatory cells. Chest. 2004;125:41S–50S.
   PubMed Web of Science ®Google Scholar
• Tateda K, Comte R, Pechere JC, et al. Azithromycin inhibits quorum sensing in Pseudomonas aeruginosa. Antimicrob Agents Chemother. 2001;45:1930–1933.
   PubMed Web of Science ®Google Scholar
• Rubin BK, Henke MO. Immunomodulatory activity and effectiveness of macrolides in chronic airway disease. Chest. 2004;125:70S–78S.
   PubMed Web of Science ®Google Scholar
• Wong C, Jayaram L, Karalus N, et al. Azithromycin for prevention of exacerbations in non-cystic fibrosis bronchiectasis (EMBRACE): A randomised, double-blind, placebo-controlled trial. Lancet. 2012;380:660–667.
   PubMed Web of Science ®Google Scholar
• Altenburg J. Effect of azithromycin maintenance treatment on infectious exacerbations among patients with non–cystic fibrosis bronchiectasis. JAMA. 2013;309:1251–1259.
   PubMed Web of Science ®Google Scholar
• Serisier DJ, Martin ML, McGuckin MA, et al. Effect of long-term, low-dose erythromycin on pulmonary exacerbations among patients with non-cystic fibrosis bronchiectasis: the BLESS randomized controlled trial. JAMA. 2013;309:1260–1267.
   PubMed Web of Science ®Google Scholar
• Currie DC, Garbett ND, Chan KL, et al. Double-blind randomized study of prolonged higher-dose oral amoxycillin in purulent bronchiectasis. Q J Med. 1990;76:799–816.
   PubMedGoogle Scholar
• Brodt AM, Stovold E, Zhang L. Inhaled antibiotics for stable non-cystic fibrosis bronchiectasis: a systematic review. Eur Respir J. 2014;44:382–393.
   PubMed Web of Science ®Google Scholar
• Murray MP, Govan JR, Doherty CJ, et al. A randomised controlled trial of nebulized gentamicin in non-cystic fibrosis bronchiectasis. Am J Respir Crit Care Med. 2011;183:491–499.
   PubMed Web of Science ®Google Scholar
• Serisier DJ, Bilton D, De Soyza A, et al. Inhaled, dual release liposomal ciprofloxacin in non-cystic fibrosis bronchiectasis (ORBIT-2): a randomised, double-blind, placebo-controlled trial. Thorax. 2013;68:812–817.
   PubMed Web of Science ®Google Scholar
• Wilson R, Welte T, Polverino E, et al. Ciprofloxacin dry powder for inhalation in non-cystic fibrosis bronchiectasis: a phase II randomised study. Eur Respir J. 2013;41:1107–1115.
   PubMed Web of Science ®Google Scholar
• Haworth CS, Foweraker JE, Wilkinson P, et al. Inhaled colistin in patients with bronchiectasis and chronic Pseudomonas aeruginosa infection. Am J Respir Crit Care Med. 2014;189:975–982.
   PubMed Web of Science ®Google Scholar
• De Soyza A, Aksamit T, Bandel TJ, et al. RESPIRE 1: a phase III placebo-controlled randomised trial of ciprofloxacin dry powder for inhalation in non-cystic fibrosis bronchiectasis. Eur Respir J. 2018;51:1702052.
   PubMed Web of Science ®Google Scholar
• Aksamit T, De Soyza A, Bandel TJ, et al. RESPIRE 2: a phase III placebo-controlled randomised trial of ciprofloxacin dry powder for inhalation in non-cystic fibrosis bronchiectasis. Eur Respir J. 2018;51:1702053.
   PubMed Web of Science ®Google Scholar
• Barker AF, O’Donnell AE, Flume P, et al. Aztreonam for inhalation solution in patients with non-cystic fibrosis bronchiectasis (AIR-BX1 and AIR-BX2): two randomised double-blind, placebo-controlled phase 3 trials. Lancet Respir Med. 2014;2:738–749.
   PubMed Web of Science ®Google Scholar
• Haworth C, Wanner A, Froehlich J, et al. Inhaled liposomal ciprofloxacin in patients with bronchiectasis and chronic Pseudomonas aeruginosa infection: results from two parallel phase III trials (ORBIT-3 and −4). Am J Respir Crit Care Med. 2017;195:A7604.
   Web of Science ®Google Scholar
• Hoppentocht M, Akkerman OW, Hagedoorn P, et al. Tolerability and pharmacokinetic evaluation of inhaled dry powder tobramycin free base in non-cystic fibrosis bronchiectasis patients. PLoS One. 2016;11:e0149768.
   PubMed Web of Science ®Google Scholar
• Flume PA, VanDevanter DR, Morgan EE, et al. A phase 3, multi-center, multinational, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of levofloxacin inhalation solution (APT-1026) in stable cystic fibrosis patients. J Cyst Fibros. 2016;15:495–502.
   PubMed Web of Science ®Google Scholar
• Martin-Loeches I, Dale GE, Torres A. Murepavadin: a new antibiotic class in the pipeline. Expert Rev Anti Infect Ther. 2018;16(4):259–268.
   PubMed Web of Science ®Google Scholar
• Kumar A, Alam A, Rani M, et al. Biofilms: survival and defense strategy for pathogens. Int J Med Microbiol. 2017;307:481–489.
   PubMed Web of Science ®Google Scholar
• White L, Mirrani G, Grover M, et al. Outcomes of Pseudomonas eradication therapy in patients with non-cystic fibrosis bronchiectasis. Respir Med. 2012;106:356–360.
   PubMed Web of Science ®Google Scholar
• Orriols R, Hernando R, Ferrer A, et al. Eradication therapy against Pseudomonas aeruginosa in non-cystic fibrosis bronchiectasis. Respiration. 2015;90:299–305.
   PubMed Web of Science ®Google Scholar
• Makris D, Moschandreas J, Damianaki A, et al. Exacerbations and lung function decline in COPD: new insights in current and ex-smokers. Respir Med. 2007;101(6):1305–1312.
   PubMed Web of Science ®Google Scholar
• Soler-Cataluña JJ, Martínez-García MA, Román Sánchez P, et al. Severe acute exacerbations and mortality in patients with chronic obstructive pulmonary disease. Thorax. 2005;60:925–931.
   PubMed Web of Science ®Google Scholar
• Hurst JR, Donaldson GC, Quint JK, et al. Temporal clustering of exacerbations in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2009;179(5):369–374.
   PubMed Web of Science ®Google Scholar
• Wedzicha JA, Seemungal TAR. COPD exacerbations: defining their cause and prevention. Lancet. 2007;370:786–796.
   PubMed Web of Science ®Google Scholar
• Gomez C, Chanez P. The lung microbiome: the perfect culprit for COPD exacerbations? Eur Respir J. 2016;47:1034–1036.
   PubMed Web of Science ®Google Scholar
• Domenech A, Puig C, Marti S, et al. Infectious etiology of acute exacerbations in severe COPD patients. J Infect. 2013;67:516–523.
   PubMed Web of Science ®Google Scholar
• Woodhead M, Blasi F, Ewig S, et al. Guidelines for the management of adult lower respiratory tract infections –full version. Clin Microbiol Infect. 2011;17(Suppl. 6):E1–E59.
   PubMed Web of Science ®Google Scholar
• Sethi S, Evans N, Grant BJB, et al. New strains of bacteria and exacerbations of chronic obstructive pulmonary disease. N Engl J Med. 2002;347:465–471.
   PubMed Web of Science ®Google Scholar
• Rosell A, Monso E, Soler N, et al. Microbiologic determinants of exacerbation in chronic obstructive pulmonary disease. Arch Intern Med. 2005;165:891–897.
   PubMed Web of Science ®Google Scholar
• Barker BL, Haldar K, Patel H, et al. Association between pathogens detected using quantitative polymerase chain reaction with airway inflammation in COPD at stable state and exacerbations. Chest. 2015;147:46–55.
   PubMed Web of Science ®Google Scholar
• Vollenweider DJ, Jarrett H, Steurer-Stey CA, et al. Antibiotics for exacerbations of chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2012;12:CD010257.
   PubMedGoogle Scholar
• Rodrigo-Troyano A, Suarez-Cuartin G, Peiro M, et al. Pseudomonas aeruginosa resistance patterns and clinical outcomes in hospitalized exacerbations of COPD. Respirology. 2016;21:1235–1242.
   PubMed Web of Science ®Google Scholar
• Wang Z, Bafadhel M, Haldar K, et al. Lung microbiome dynamics in COPD exacerbation. Eur Respir J. 2016;47:1082–1092.
   PubMed Web of Science ®Google Scholar
• James GDR, Petersen I, Nazareth I, et al. Use of long-term antibiotic treatment in COPD patients in the UK: a retrospective cohort study. Prim Care Respir J. 2013;22:271–277.
   PubMedGoogle Scholar
• Sethi S, Jones PW, Theron MS, et al. Pulsed moxifloxacin for the prevention of exacerbations of chronic obstructive pulmonary disease: a randomized controlled trial. Respir Res. 2010;11:10.
   PubMed Web of Science ®Google Scholar
• Uzun S, Djamin RS, Kluytmans JAJW, et al. Azithromycin maintenance treatment in patients with frequent exacerbations of chronic obstructive pulmonary disease (COLUMBUS): a randomised, double-blind, placebo-controlled trial. Lancet Respir Med. 2014;2:361–368.
   PubMed Web of Science ®Google Scholar
• MÁ M-G, la Rosa Carrillo de D, Soler-Cataluña JJ, et al. Prognostic value of bronchiectasis in patients with moderate-to-severe chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2013;187:823–831.
   PubMed Web of Science ®Google Scholar
• Wenzel RP, Fowler AA, Edmond MB. Antibiotic prevention of acute exacerbations of COPD. N Engl J Med. 2012;367:340–347.
   PubMed Web of Science ®Google Scholar
• Han MK, Tayob N, Murray S, et al. Predictors of chronic obstructive pulmonary disease exacerbation reduction in response to daily azithromycin therapy. Am J Respir Crit Care Med. 2014;189:1503–1508.
   PubMed Web of Science ®Google Scholar
• Smith NL, Denning DW. Underlying conditions in chronic pulmonary aspergillosis including simple aspergilloma. Eur Respir J. 2011;37:865–872.
   PubMed Web of Science ®Google Scholar
• Denning DW, Cadranel J, Beigelman-Aubry C, et al. Chronic pulmonary aspergillosis: rationale and clinical guidelines for diagnosis and management. Eur Respir J. 2016;47:45–68.
   PubMed Web of Science ®Google Scholar
• Patterson TF, Thompson GR, Denning DW, et al. Practice guidelines for the diagnosis and management of aspergillosis: 2016 update by the Infectious Diseases Society of America. Clin Infect Dis. 2016;63:e1–e60.
   PubMed Web of Science ®Google Scholar
• Griffith DE, Aksamit T, Brown-Elliott BA, et al. An official ATS/IDSA statement: diagnosis, treatment, and prevention of nontuberculous mycobacterial diseases. Am J Respir Crit Care Med. 2007;175:367–416.
   PubMed Web of Science ®Google Scholar
• Zuckerman JM, Qamar F, Bono BR. Review of macrolides (azithromycin, clarithromycin), ketolids (telithromycin) and glycylcyclines (tigecycline). Med Clin North Am. 2011;95:761–791.
   PubMed Web of Science ®Google Scholar
• Griffith DE, Brown BA, Girard WM, et al. Azithromycin-containing regimens for treatment of Mycobacterium avium complex lung disease. Clin Infect Dis. 2001;32:1547–1553.
   PubMed Web of Science ®Google Scholar
• Lam PK, Griffith DE, Aksamit TR, et al. Factors related to response to intermittent treatment of Mycobacterium avium complex lung disease. Am J Respir Crit Care Med. 2006;173:1283–1289.
   PubMed Web of Science ®Google Scholar
• Koh WJ, Hong G, Kim SY, et al. Treatment of refractory Mycobacterium avium complex lung disease with a moxifloxacin-containing regimen. Antimicrob Agents Chemother. 2013;57:2281–2285.
   PubMed Web of Science ®Google Scholar
• Kobashi Y, Matsushima T, Oka M. A double-blind randomized study of aminoglycoside infusion with combined therapy for pulmonary Mycobacterium avium complex disease. Respir Med. 2007;101:130–138.
   PubMed Web of Science ®Google Scholar
• Choi GE, Min KN, Won CJ, et al. Activities of moxifloxacin in combination with macrolides against clinical isolates of Mycobacterium abscessus and Mycobacterium massiliense. Antimicrob Agents Chemother. 2012;56:3549–3555.
   PubMed Web of Science ®Google Scholar
• Wallace RJ, Brown-Elliott BA, McNulty S, et al. Macrolide/azalide therapy for nodular/bronchiectatic Mycobacterium avium complex lung disease. Chest. 2014;146:276–282.
   PubMed Web of Science ®Google Scholar
• Zoumot Z, Boutou AK, Gill SS, et al. Mycobacterium avium complex infection in non-cystic fibrosis bronchiectasis. Respirology. 2014;19:714–722.
   PubMed Web of Science ®Google Scholar
• Biancardi E, Fennell M, Rawlinson W, et al. Viruses are frequently present as the infecting agent in acute exacerbations of chronic obstructive pulmonary disease in patients presenting to hospital. Intern Med J. 2016;46:1160–1165.
   PubMed Web of Science ®Google Scholar
• Footitt J, Mallia P, Durham AL, et al. Oxidative and nitrosative stress and histone deacetylase-2 activity in exacerbations of COPD. Chest. 2016;149:62–73.
   PubMed Web of Science ®Google Scholar
• Mallia P, Footitt J, Sotero R, et al. Rhinovirus infection induces degradation of antimicrobial peptides and secondary bacterial infection in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2012;186:1117–1124.
   PubMed Web of Science ®Google Scholar
• Dobson J, Whitley RJ, Pocock S, et al. Oseltamivir treatment for influenza in adults: a meta-analysis of randomized controlled trials. Lancet. 2015;385:1729–1737.
   PubMed Web of Science ®Google Scholar
• Robert JN, Graham BS, Karron RA, et al. Challenges and opportunities in RSV vaccine development: 343 Meeting report from FDA/NIH workshop. Vaccine. 2016;34(41):4843–4849.
   PubMed Web of Science ®Google Scholar
• Tominaga N, Edeki T, Li J, et al. Phase I study assessing the safety, tolerability, and pharmacokinetics of avibactam and ceftazidime–avibactam in healthy Japanese volunteers. J Infect Chemother. 2015;21:551–558.
   PubMed Web of Science ®Google Scholar
• Sader HS, Farrell DJ, Castanheira M, et al. Antimicrobial activity of ceftolozane/tazobactam tested against Pseudomonas aeruginosa and Enterobacteriaceae with various resistance patterns isolated in European hospital (2011–12). J Antimicrob Chemother. 2014;69:2713–2722.
   PubMed Web of Science ®Google Scholar
• Zhanel GG, Golden AR, Zelenitsky S, et al. Cefiderocol: A siderophore cephalosporin with activity against carbapenem-resistant and multidrug-resistant gram-negative bacilli. Drugs. 2019;79(3):271.
   PubMed Web of Science ®Google Scholar
• Longcor J, Hopkins S, Wickler M, et al. A phase 2 study of the safety and efficacy of oral delafloxacin (DLX) in community acquired pneumonia (CAP). Presented at IDWeek 2012, San Diego, CA; October 16–21, 2012.
   Google Scholar
• Barrera CM, Mykietiuk A, Metev H, et al. Efficacy and safety of oral solithromycin versus oral moxifloxacin for treatment of community-acquired bacterial pneumonia: a global, double-blind, multicentre, randomised, active-controlled, non-inferiority trial (SOLITAIRE-ORAL). Lancet Infect Dis. 2016;16:421–430.
   PubMed Web of Science ®Google Scholar
• FDA Briefing document Solithromycin Oral Capsule and Injection Meeting of the Antimicrobial Drugs Advisory Committee (AMDAC); 2016 Nov 4. Available from: https://www.fda.gov
   Google Scholar
• van Ingen J, Totten SE, Helstrom NK, et al. In vitro synergy between clofazimine and amikacin in treatment of nontuberculous mycobacterial disease. Antimicrob Agents Chemother. 2012;56:6324–6337.
   PubMed Web of Science ®Google Scholar
• Jarand J, Davis JP, Cowie RL, et al. Long-term follow-up of Mycobacterium avium complex lung disease in patients treated with regimens including clofazimine and/or rifampin. Chest. 2016;149:1285–1293.
   PubMed Web of Science ®Google Scholar
• Zhao W, Jiang Y, Bao P, et al. Evaluation of the efficacy of novel oxazolidinone analogues against nontuberculous mycobacteria in vitro. Jpn J Infect Dis. 2015;68:520–522.
   PubMed Web of Science ®Google Scholar
• Locher CP, Jones SM, Hanzelka BL, et al. A novel inhibitor of gyrase B is a potent drug candidate for treatment of tuberculosis and nontuberculosis mycobacterial infections. Antimicrob Agents Chemother. 2015;59:1455–1465.
   PubMed Web of Science ®Google Scholar
• Krieger D, Schönfeld N, Vesenbeckh S, et al., Is delamanid a potential agent in the treatment of diseases caused by Mycobacterium avium-intracellulare ? Eur Respir J. 48(6): 1803–1804. 2016.
   PubMed Web of Science ®Google Scholar